Altamira Therapeutics Ltd. (CYTO)
NASDAQ: CYTO · Real-Time Price · USD
0.425
-0.015 (-3.39%)
Nov 21, 2024, 11:01 AM EST - Market open
Altamira Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 0.07 | 0.62 | 0.02 | 0.98 | 11.26 | 1.38 | Upgrade
|
| Cash & Short-Term Investments | 0.07 | 0.62 | 0.02 | 0.98 | 11.26 | 1.38 | Upgrade
|
| Cash Growth | 32.05% | 3910.45% | -98.44% | -91.26% | 713.08% | -74.32% | Upgrade
|
| Accounts Receivable | - | - | 0.01 | 0.02 | - | - | Upgrade
|
| Other Receivables | 0.12 | 0.07 | 0.76 | 0.66 | 0.06 | 0.23 | Upgrade
|
| Receivables | 0.12 | 0.07 | 0.76 | 0.69 | 0.06 | 0.23 | Upgrade
|
| Inventory | - | - | 0.01 | 0.84 | - | - | Upgrade
|
| Prepaid Expenses | 0.08 | 0.07 | 0.05 | 0.14 | 0.11 | 0.13 | Upgrade
|
| Other Current Assets | 0.26 | 0.46 | 0.93 | 1.45 | 0.19 | 0.63 | Upgrade
|
| Total Current Assets | 0.52 | 1.22 | 1.77 | 4.09 | 11.62 | 2.37 | Upgrade
|
| Property, Plant & Equipment | 0.42 | 0.08 | 0.45 | 0.56 | 0.05 | 0.07 | Upgrade
|
| Long-Term Investments | 2.5 | 2.5 | 0.19 | 0.2 | - | - | Upgrade
|
| Other Intangible Assets | 4.63 | 3.89 | 3.89 | 14.31 | 9.12 | 6.77 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | - | 0.02 | Upgrade
|
| Total Assets | 8.07 | 7.69 | 6.3 | 19.17 | 20.8 | 9.23 | Upgrade
|
| Accounts Payable | 0.53 | 0.41 | 4.77 | 3.54 | 0.72 | 0.91 | Upgrade
|
| Accrued Expenses | 0.58 | 0.35 | 1.98 | 1.05 | 1.43 | 1.34 | Upgrade
|
| Short-Term Debt | - | - | 5.87 | - | 0.52 | - | Upgrade
|
| Current Portion of Leases | 0.12 | 0.1 | 0.12 | 0.11 | - | - | Upgrade
|
| Other Current Liabilities | - | 0.03 | 0.15 | 0.15 | 0.35 | 0.03 | Upgrade
|
| Total Current Liabilities | 1.23 | 0.89 | 12.88 | 4.86 | 3.03 | 2.28 | Upgrade
|
| Long-Term Leases | 0.3 | - | 0.34 | 0.46 | - | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | 0.93 | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 0.13 | 0.14 | 0.13 | 0.15 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0 | 0.01 | 0 | Upgrade
|
| Total Liabilities | 1.75 | 1.24 | 14.62 | 6.13 | 4.03 | 3.19 | Upgrade
|
| Common Stock | 0.01 | 0 | 0.24 | 0.15 | 0.11 | 1.65 | Upgrade
|
| Additional Paid-In Capital | - | 20.1 | 192.62 | 188.51 | 177.23 | 157.19 | Upgrade
|
| Retained Earnings | 1.26 | -18.05 | -201.43 | -175.69 | -160.64 | -152.78 | Upgrade
|
| Comprehensive Income & Other | 5.05 | 4.4 | 0.26 | 0.06 | 0.06 | -0.03 | Upgrade
|
| Shareholders' Equity | 6.32 | 6.46 | -8.31 | 13.04 | 16.77 | 6.04 | Upgrade
|
| Total Liabilities & Equity | 8.07 | 7.69 | 6.3 | 19.17 | 20.8 | 9.23 | Upgrade
|
| Total Debt | 0.43 | 0.1 | 6.33 | 0.58 | 0.52 | - | Upgrade
|
| Net Cash (Debt) | -0.36 | 0.52 | -6.32 | 0.41 | 10.73 | 1.38 | Upgrade
|
| Net Cash Growth | - | - | - | -96.20% | 675.24% | -65.01% | Upgrade
|
| Net Cash Per Share | -0.26 | 1.05 | -138.70 | 12.33 | 714.00 | - | Upgrade
|
| Filing Date Shares Outstanding | 2.67 | 2.24 | 0.35 | 0.04 | 0.03 | 0.01 | Upgrade
|
| Total Common Shares Outstanding | 2.67 | 1.48 | 0.06 | 0.04 | 0.03 | 0.01 | Upgrade
|
| Working Capital | -0.7 | 0.33 | -11.11 | -0.77 | 8.59 | 0.1 | Upgrade
|
| Book Value Per Share | 2.37 | 4.37 | -140.92 | 348.46 | 587.53 | 585.18 | Upgrade
|
| Tangible Book Value | 1.69 | 2.57 | -12.21 | -1.28 | 7.65 | -0.73 | Upgrade
|
| Tangible Book Value Per Share | 0.63 | 1.74 | -206.91 | -34.18 | 268.17 | -70.72 | Upgrade
|
| Machinery | - | 0.59 | 0.59 | 0.59 | 0.59 | 0.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.